Negr1-Derived Peptides Trigger ALK Degradation and Halt Neuroblastoma Progression In Vitro and In Vivo

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Neuroblastoma is a prevalent and challenging pediatric cancer, with advanced stages often resistant to current treatments.
• Anaplastic Lymphoma Kinase (ALK) mutations are key drivers in hereditary and sporadic neuroblastoma, making ALK a primary therapeutic target.
• Resistance to ALK inhibitors can lead to relapse, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate the role of Immunoglobulin-like domain containing, cell adhesion molecule 1 (IgLON1), specifically Negr1, in neuroblastoma.
• To evaluate the therapeutic potential of Negr1 protein and its derived peptides in preclinical neuroblastoma models.

Main Methods:

• Analysis of Negr1 expression in neuroblastoma samples.
• In vitro and in vivo experiments involving ectopic Negr1 overexpression.
• Characterization of Negr1 protein and derived peptides.
• Assessment of ALK downregulation and neuroblastoma progression following Negr1-based treatment.

Main Results:

• Negr1 expression is downregulated in neuroblastoma.
• Ectopic Negr1 expression inhibits neuroblastoma cell growth both in vitro and in vivo.
• Treatment with Negr1 protein and peptides effectively downregulates ALK and halts tumor progression.
• Negr1 functions as both a membrane-bound and soluble protein, with peptides demonstrating therapeutic efficacy.

Conclusions:

• Negr1 represents a novel tumor suppressor in neuroblastoma.
• Negr1 protein and its derived peptides show significant therapeutic promise for treating neuroblastoma by targeting ALK.
• This study introduces a new therapeutic avenue for managing advanced neuroblastoma and overcoming resistance mechanisms.